Stryker Completes Acquisition of Inari

February 19, 2025—Stryker announced that it has completed the acquisition of Inari Medical, Inc., a provider of solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. On January 6, 2025, Stryker announced a definitive agreement to acquire Inari for approximately $4.9 billion.

Stryker stated that Inari’s product portfolio includes two mechanical thrombectomy devices—the FlowTriever system for the treatment of pulmonary embolism and the ClotTriever system for thrombectomy in the peripheral vessels. Inari’s portfolio, which also includes emerging therapies, is complementary to Stryker’s neurovascular business, noted the company.

Inari shares ceased trading and it was delisted from the Nasdaq Global Select Market, advised Stryker.